[Federal Register Volume 62, Number 115 (Monday, June 16, 1997)] [Notices] [Pages 32617-32618] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 97-15635] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 97D-0214] Draft Guidance for Industry on Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled ``Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling.'' The draft guidance is intended for sponsors planning to conduct studies to assess the influence of renal impairment on the pharmacokinetics and pharmacodynamics of an investigational drug. DATES: Written comments may be submitted on the draft guidance by August 15, 1997. General comments on the agency guidance documents are welcome at any time. ADDRESSES: Submit written requests for single copies of ``Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling'' to the Drug Information Branch (HFD-210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Dockets Management Branch (HFA-305), Food and Drug [[Page 32618]] Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. FOR FURTHER INFORMATION CONTACT: Shiew-Mei Huang, Center for Drug Evaluation and Research (HFD-850), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5671. SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a draft guidance entitled ``Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling.'' The pharmacokinetics (PK) and pharmacodynamics (PD) of drugs primarily eliminated through the kidneys may be altered by impaired renal function to the extent that the dosage regimen needs to be changed from that used in patients with normal renal function. Although the most obvious type of change arising from renal impairment is a decrease in renal excretion (or possibly renal metabolism) of a drug or its metabolites, renal impairment also has been associated with other changes, such as changes in hepatic metabolism, plasma protein binding, and drug distribution. These changes may be particularly prominent in patients with severely impaired renal function and have been observed even when the renal route is not the primary route of elimination of a drug. Thus, for most drugs that are likely to be administered to patients with renal impairment, PK/PD characterization may need to be assessed in subjects with such impairment to provide appropriate dosing recommendations. The draft guidance provides specific information on when studies of PK in patients with impaired renal function should be performed and when they may be unnecessary. It also addresses the design and conduct of PK/PD studies in patients with impaired renal function, the design and conduct of PK/PD studies in end stage renal disease (ESRD) patients treated with hemodialysis, the analysis and reporting of the results of such studies, and representation of these results in approved product labeling. This draft guidance represents the agency's current thinking on conducting PK/PD studies on patients with impaired renal function. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirement of the applicable statute, regulations, or both. Interested persons may submit written comments on the draft guidance to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. An electronic version of this draft guidance is available on the Internet using the World Wide Web (www) at http://www.fda.gov/cder/ guidance.htm. Dated: June 6, 1997. William K. Hubbard, Associate Commissioner for Policy Coordination. [FR Doc. 97-15635 Filed 6-13-97; 8:45 am] BILLING CODE 4160-01-F